Analyst consensus rating
Vir Biotechnology Analyst Rating: none
VIR is rated none by 9 analysts with a $21.00 target. As of 2026-08-31.
Direct answer
Vir Biotechnology's consensus rating is none.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $21.00.
Forecast evidence checked August 31, 2026.
Get free Vir Biotechnology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $11.16
- Average price target
- $21.00
- High price target
- $30.00
- Low price target
- $15.00
- Low target gap
- +34.4%
- Target upside
- +88.2%
- High target gap
- +168.8%
- Target range width
- 134.4%
- Consensus rating
- none
- Analysts
- 9
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Vir Biotechnology?
Vir Biotechnology has a verified none consensus. The same dataset has an average price target of $21.00.
How far are Vir Biotechnology's low and high targets from the recorded price?
The low target implies +34.4%, while the high target implies +168.8%.
How many analysts are included in Vir Biotechnology's consensus?
The verified consensus includes 9 analysts.
How is Vir Biotechnology's target upside or downside calculated?
The average target of $21.00 is divided by the recorded price of $11.16, then one is subtracted to produce +88.2%. This does not guarantee a future return.
When was Vir Biotechnology's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.